排序方式: 共有23条查询结果,搜索用时 18 毫秒
11.
目的 观察不同浓度的6-(4-取代苯甲酰氨基苯基)哒嗪酮类化合物对二磷酸腺苷(ADP)诱导血小板聚集的抑制作用.方法 将不同浓度的6-(4-取代苯甲酰氨基苯基)哒嗪酮类化合物分别加入人富含血小板血浆(PRP)中,用多功能血小板聚集仪测定ADP诱导的血小板聚集作用.结果 该新哒嗪酮类化合物对ADP诱导血小板聚集有剂量依赖性抑制作用,其半数抑制浓度IC50(μmol/L)分别为1.04、2.80、3.01、7.32.结论 6-(4-取代苯甲酰氨基苯基)哒嗪酮类化合物具有较强的抑制ADP诱导的血小板聚集作用. 相似文献
12.
Design and synthesis of nitrogen-fused pyridazinone fluorescent probes and their application in biological imaging 下载免费PDF全文
A series of small-molecular fluorescent probes based on nitrogen-fused pyridazinone scaffold were developed in this report. The design strategy involved two steps: 1) enhancing the electron-withdrawing ability of the acceptor by incorporatingan N-heterocyclic aromatic ring (pyridine or pyrazine) at the C4 and C5 positions of the pyridazinone skeleton and 2) anchoring a triphenylphosphine or morpholine tail as the subcellular targeting group. These fluorescent probes displayed excellent properties in live cell and brain tissue imaging. 相似文献
13.
Some novel derivatives of 2-alkyl 6-substituted pyridazin-3(2H)-ones were synthesized by condensation of 3,6-dichloropyridazine with the sodium salt of benzyl cyanide, followed by hydrolysis and coupling with alkyl halides. The synthesized compounds were screened as cyclooxygenase (COX)-1/COX-2 inhibitors and as analgesic and anti-inflammatory agents. Among the synthesized compounds, 6-benzyl-2-methylpyridazin-3(2H)-one ( 4a ), 6-benzoyl-2-propylpyridazin-3(2H)-one ( 8b ), and 6-(hydroxy(phenyl)methyl)-2-methylpyridazin-3(2H)-one ( 9a ) displayed the highest COX-2 selectivity indices of 96, 99, and 98, respectively, and analgesic efficacies of 47%, 46%, and 45% protection, respectively. Also, compounds 4a , 8b , and 9a showed anti-inflammatory activities of 65%, 60%, and 62% inhibition of edema, respectively, at a dose of 10 mg/kg, which is higher than that of diclofenac (58% inhibition of edema). 相似文献
14.
由芳香醛与吗啡啉、氰化钾反应形成的α-芳基-α-(4-吗啡啉)乙腈,可对α,β-不饱合腈或酯进行加成,形成γ-氰基-γ-芳基-γ-(4-吗啡啉)丁酸乙脂。此物与肼缩合得6-取代芳基-4,5-二氢-3(2 H)哒嗪酮,其经芳构化可得6-取代芳基-3(2 H)哒嗪酮。本文报道了7个6-取代芳基-4,5-二氢-3(2 H)哒嗪酮及7个6-取代芳基-3(2 H)哒嗪酮的合成。药理实验表明,其中以2,4-二氯苯基-3(2 H)哒嗪酮的抗惊作用最强,芳环上的取代基对其生物活性具有一定影响。 相似文献
15.
本文对2′,4′-二氯苯基哒嗪衍生物对几种实验性癫痫模型的对抗作用进行了研究,其中化合物Ⅰ和Ⅱ对最大电休克发作实验(MEST),戊四唑(Met)印防己毒素发作和荷包牡丹碱发作等四种实验性癫痫模型均有很强的对抗作用,强于苯妥英钠,苯巴比妥和卡马西平,但也显示中枢抑制作用,预防指数不高,化合物Ⅲ和Ⅳ对这四种动物惊厥模型亦有较强的对抗作用,均大大强于丙戊酸钠和乙琥胺,其中化合物Ⅲ的中枢神经系统毒性较低,抗MEST的预防指数高达23.4. 相似文献
16.
D.B. Evans R.E. Potoczak R.P. Steffen W.E. Burmeister R.W. McNish J.A. Schenden H.R. Kaplan 《Drug development research》1986,9(2):143-157
Imazodan is a novel pyridazinone derivative. It was evaluated in excised cardiac tissue, anesthetized dogs and monkeys, and conscious dogs. Imazodan, 10?5–10?3M, produced dose-dependent increases in guinea pig atrial and rabbit papillary muscle contractility. In ansthetized dogs and rhesus monkeys, imazodan, 0.001–1.0 mg/kg IV, produced dosedependent increases of 10–150% in myocardial contractility (dP/dt max of left ventricular pressure), and decreases of 1–31% in aortic blood pressure. Heart rate increases were minimal (0–34%) in comparison to the changes in contractility and they occurred only at the higher doses. The positive inotropic action of imazodan was not blocked by β-adrenoceptor blockade with propranolol. Forelimb perfusion studies in the anesthetized dog demonstrated that imazodan produces a dose-dependent direct peripheral vasodilator action. This agent was also demonstrated to be a highly effective cardiotonic when administered orally (0.1–1.0 mg/kg) to conscious dogs. The results of these studies indicate that imazodan is an orally effective cariotonic that possesses balanced positive inotrophic and peripheral vasodilator activities and possesses a wide margin of cardiac safety. 相似文献
17.
以具有抗血小板聚集活性的苯并咪唑类化合物和哒嗪酮类化合物为先导化合物 ,运用药物化学的拼合原理 ,设计并合成了 6个新的苯并咪唑 哒嗪酮类化合物及 6个新的苯并咪唑 苯并哒嗪酮类化合物 ,并经NMR和MS进行了结构鉴定 ,对其进行了抗血小板聚集的药理活性筛选。结果表明所合成目标化合物基本无抗血小板聚集活性 相似文献
18.
6-(4′-取代酰胺基苯基)-4,5-二氢-3(2H)-哒嗪酮类化合物的合成及其抑制血小板聚集作用 总被引:1,自引:0,他引:1
目的:6-(4′-取代苯基)-4,5-二氢-3(2H)-哒嗪酮类化合物的合成及抗血小板聚集活性的研究。方法:通过付-克反应、碳链延长、水解和环合反应得到两个关键中间体,然后通过酰化反应制得各种酰胺化合物;参考Born比浊法测定目标化合物的抗血小板聚集活性。结果:设计合成了24个6-(4′-取代酰胺基苯基)-4,5-二氢-3(2H)-哒嗪酮类化合物,22个为首次报道;所有化合物在体外对ADP诱导的兔血小板聚集均有不同程度的抑制作用,第II类化合物的抑制作用强于第I类化合物,其中I1,I3,II1,II3,II4,II6和II9的抑制作用均强于对照药CI-930,其中II1和II3的抑制作用最强,其IC50约为CI-930的1/10。结论:其中一些化合物显示较强的抗血小板聚集活性,值得进一步研究。 相似文献
19.
目的:6(4′取代苯基)4,5二氢3(2H)哒嗪酮类化合物的合成及抗血小板聚集活性的研究。方法:通过付克反应、碳链延长、水解和环合反应得到两个关键中间体,然后通过酰化反应制得各种酰胺化合物;参考Born比浊法测定目标化合物的抗血小板聚集活性。结果:设计合成了24个6(4′取代酰胺基苯基)4,5二氢3(2H)哒嗪酮类化合物,22个为首次报道;所有化合物在体外对ADP诱导的兔血小板聚集均有不同程度的抑制作用,第II类化合物的抑制作用强于第I类化合物,其中I1,I3,II1,I3,II4,I6和II9的抑制作用均强于对照药CI930,其中I1和II3的抑制作用最强,其IC50约为CI930的1/10。结论:其中一些化合物显示较强的抗血小板聚集活性,值得进一步研究。 相似文献
20.
本文采用比较分子力场分析法(CoMFA),系统研究了自行合成的34个6-[4-(取代哌嗪基)苯基]-4,5-二氢-3(2H)-哒嗪酮类化合物和参比化合物CCI-17810的三维定量构效关系.所建立CoMFA模型的交叉相关系数q2值为0.663,具有较强的预测能力.利用CoMFA模型的三维等值线图直观地解释了化合物的构效关系,阐明了化合物结构中哌嗪末端N原子上不同取代基对抗血小板聚集活性的影响,为进一步结构优化提供了重要信息. 相似文献